Alnyalm, Vir partner on RNAi-based drugs for infectious diseases

(Reuters) - Drug developer Alnylam Pharmaceuticals Inc entered into an agreement with privately held Vir Biotechnology on Wednesday to develop a new class of RNAi-based treatments for infectious diseases, including chronic hepatitis B.